Andrew Booth, Chief Financial Officer at AbCellera Biologics Inc. (ABCL), bought 85,000 shares at $5.79 ($492K) on 2022-05-12, disclosed to the SEC on 2022-05-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| ABCL | BUY | 2023-05-26 | $99K | — | Filing → |
| ABCL | BUY | 2021-11-15 | $993K | — | Filing → |
| ABCL | SELL | 2021-06-10 | $30.6M | — | Filing → |